Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Bellinzona
Clinical trial register · Switzerland

Clinical Trials in Bellinzona, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Switzerland and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2249 matching records held by the registry are in this view. Synced 12 Nov 2026, 03:18 UTC
2249
Studies in scope
all four open statuses
1364
Recruiting now
open to new participants
528
Lead sponsors
across recruiting studies
Top sites
Zurich 739 Bern 722 Basel 636 Geneva 406 Lausanne 394
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Swiss Cancer Institute15 Merck Sharp & Dohme LLC13 Oncology Institute of Southern Switzerland10 International Extranodal Lymphoma Study Group (IELSG)9 Bristol-Myers Squibb6 European Organisation for Research and Treatment of Cancer - EORTC5 AstraZeneca5 Stichting Hemato-Oncologie voor Volwassenen Nederland5 Incyte Corporation5 Novartis Pharmaceuticals4 Ente Ospedaliero Cantonale, Bellinzona4 University of Bern4 Amgen3 Insel Gruppe AG, University Hospital Bern3 Institute of Cancer Research, United Kingdom3 Andrea Saporito3 ETOP IBCSG Partners Foundation3 Genmab2 Orion Corporation, Orion Pharma2 Philogen S.p.A.2 University Hospital Muenster2 University of Birmingham2 Loxo Oncology, Inc.2 Gustave Roussy, Cancer Campus, Grand Paris2 AbbVie2 Show all 57
Site location
Zurich739 Bern722 Basel636 Geneva406 Lausanne394 Sankt Gallen272 Lucerne152 Bellinzona148 Aarau136 Lugano131 Chur99 Baden81 Winterthur81 Fribourg72 Liestal35 Olten32 Sion24 Frauenfeld22 Thun19 Münsterlingen15 Nottwil15 Biel14 Neuchâtel13 Solothurn12 Meyrin12 Show all 151
All 151 locations
Target enrolment
to

Trials with a site in Bellinzona

148 of 2249 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Switzerland
Start
Not yet open
Best Salvage Treatment for High-risk Relapsing Prostate Cancer (PEACE-9 - ESCALATE-RT)
NCT07782112Prostatic Neoplasms, Biochemical Recurrence, Oligometastatic Prostate Cancer
DrugEnzalutamide
Ente Ospedaliero Cantonale, Bellinzona
Phase 3
140
Aarau, Bellinzona, Bern, Chur, Münsterlingen, Winterthur, Zurich
2026-11
Not yet open
University Hospital, Basel, Switzerland
Phase 2
66
Basel, Biel/Bienne, Sankt Gallen, Zurich, Bellinzona
2026-11
Recruiting
Swiss Cancer Institute
Phase 2
108
Fribourg, Basel, Bellinzona, Bern, Geneva, Lausanne, Münsterlingen, Sankt Gallen
2026-10-12
Recruiting
Merck Sharp & Dohme LLC
Phase 2
200
Bellinzona, Sankt Gallen
2026-10-07
Recruiting
Swiss Cancer Institute
Phase 2
92
Aarau, Basel, Bellinzona, Bern, Chur, Geneva, Lucerne, Sankt Gallen
2026-09-24
Recruiting
A Study in Adults With Geographic Atrophy
NCT07606365Geographic Atrophy
DrugSTL303
Sitala Bio LTD
Phase 2
300
Bellinzona, Bern, Binningen, Lausanne, Zurich
2026-09-11
Not yet open
Characterization of Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL) by Multiomic Approach
NCT07147751Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL)
International Extranodal Lymphoma Study Group (IELSG)
Observational
100
Bellinzona
2026-09
Recruiting
Oncology Institute of Southern Switzerland
Not applicable
74
Bellinzona
2026-06-19
Recruiting
Merck Sharp & Dohme LLC
Phase 1
120
Sankt Gallen, Lausanne, Bellinzona
2026-06-18
Recruiting
Giving Children a Voice in Paediatric Anaesthesia
NCT07524049Perioperative Care, Pediatric Anesthesia, Pain Management, Anxiety
Insel Gruppe AG, University Hospital Bern
Observational
1,040
Aarau, Basel, Bern, Fribourg, Geneva, Lucerne, Bellinzona
2026-05-27
Recruiting
Swiss Cancer Institute
Phase 2
42
Baden, Basel, Bellinzona, Chur, Frauenfeld, Geneva, Lucerne, Rapperswil
2026-04-24
Recruiting
LUCINAE Registry: Thoracic Cancers During Pregnancy
NCT07699861Lung Cancer, Thoracic Cancer, Cancer During Pregnancy
Oncology Institute of Southern Switzerland
Observational
100
Baden, Bellinzona, Geneva, Winterthur
2026-04-23
Recruiting
Visugromab in Cachexia International Trial
NCT07112196Cancer-associated Cachexia
DrugVisugromab
CatalYm GmbH
Phase 2/3
518
Aarau, Basel, Bellinzona, Lugano, Sankt Gallen, Zurich
2026-04-16
Recruiting
Swiss Cancer Institute
Phase 2
156
Fribourg, Aarau, Baden, Basel, Bellinzona, Bern, Bülach, Chur
2026-04-10
Recruiting
Ente Ospedaliero Cantonale, Bellinzona
Not applicable
50
Bellinzona
2026-04-02
Recruiting
A 2-part Phase 1/2 Open-label Trial on ODM-212
NCT07563738Mesothelioma, Pancreatic Cancer, NSCLC (Advanced Non-small Cell Lung Cancer)
DrugsODM-212·Gemcitabine and nab-paclitaxel·Ipilimumab and nivolumab·Sotorasib
Orion Corporation, Orion Pharma
Phase 1/2
229
Bellinzona
2026-03-27
Recruiting
Lega Cancro Ticino
Not applicable
46
Bellinzona
2026-03-27
Recruiting
Bristol-Myers Squibb
Phase 3
850
Basel, Bellinzona, Münsterlingen, Sankt Gallen
2026-03-16
Recruiting
Merck Sharp & Dohme LLC
Phase 3
900
Bern, Bellinzona, Chur, Geneva
2026-02-16
Recruiting
PUSHES (Pudendal Block Versus Sacral ESP Hemorrhoidectomy Study)
NCT07350460Hemorrhoids, Hemorrhoids Third Degree
Andrea Saporito
Not applicable
64
Bellinzona
2026-01-05
Recruiting
Andrea Saporito
Not applicable
106
Bellinzona
2025-12-11
Recruiting
Incyte Corporation
Phase 3
466
Bellinzona, Chur, Frauenfeld, Geneva, Lausanne, Zurich
2025-12-09
Recruiting
Simonetti Giacomo
Observational
60
Bellinzona, Geneva
2025-12-01
Recruiting
Incyte Corporation
Phase 2
160
Bellinzona, Chur, Geneva, Lausanne
2025-11-12
Recruiting
Bristol-Myers Squibb
Phase 2/3
500
Baden, Sankt Gallen, Bellinzona
2025-11-05
Recruiting
Swiss Cancer Institute
Phase 2
24
Aarau, Basel, Bellinzona, Bern, Lausanne, Sankt Gallen, Winterthur, Zurich
2025-10-27
Active, closed
Bristol-Myers Squibb
Phase 2/3
470
Bern, Sankt Gallen, Bellinzona, Geneva
2025-10-23
Recruiting
Eli Lilly and Company
Phase 3
1,630
Baden, Bellinzona, Chur, Geneva
2025-10-22
Recruiting
International Extranodal Lymphoma Study Group (IELSG)
Observational
100
Bellinzona
2025-10-13
Active, closed
Fabiën Belle
Observational
12,150
Aarau, Basel, Bern, Geneva, Lucerne, Sankt Gallen, Zurich, Bellinzona
2025-10-01
Recruiting
Bristol-Myers Squibb
Phase 2/3
470
Sankt Gallen, Bellinzona, Chur, Zurich
2025-09-30
Recruiting
AbbVie
Observational
2,795
Aarau, Basel Town, Geneva, Lucerne, Zurich, Bellinzona, Lugano, Orsières
2025-09-02
Recruiting
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3
227
Basel, Bellinzona, Bern, Zurich
2025-08-05
Recruiting
Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer
NCT05815927Oligometastatic Squamous Cell Carcinoma of the Head and Neck
DrugPembrolizumab
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
200
Aarau, Bellinzona, Bern, Chur, Lucerne, Winterthur, Zurich
2025-05-23
Recruiting
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3
448
Aarau, Basel, Bellinzona, Bern, Geneva, Zurich
2025-05-05
Recruiting
Institute of Cancer Research, United Kingdom
Phase 1/2
78
Bellinzona
2025-04-28
Recruiting
177Lu-DOTATATE for Recurrent Meningioma
NCT06326190Recurrent Meningioma
DrugsLuTate·Lutathera
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2
136
Bellinzona, Zurich
2025-03-10
Recruiting
Novartis Pharmaceuticals
Phase 2/3
443
Basel, Bellinzona, Bern
2025-02-27
Recruiting
University of Zurich
Phase 2
120
Zurich, Aarau, Bellinzona, Bern, Geneva, Neuchâtel, Winterthur
2025-02-04
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,046
Baden, Sankt Gallen, Bellinzona, Lugano
2025-01-27
Recruiting
ETOP IBCSG Partners Foundation
Phase 3
290
Baden, Basel, Bellinzona, Bern, Fribourg, Lausanne, Sankt Gallen, Winterthur
2025-01-15
Active, closed
University of Applied Sciences and Arts of Southern Switzerland
Observational
120
Bellinzona, Manno, Morbio Inferiore, Sonvico
2024-12-17
Active, closed
Amgen
Phase 3
707
Bellinzona, Bern, Chur, Lausanne, Sankt Gallen
2024-12-09
Active, closed
Novartis Pharmaceuticals
Phase 1
110
Bellinzona, Bern
2024-11-11
Recruiting
Andrea Saporito
Not applicable
45
Bellinzona
2024-11-01
Recruiting
Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK
NCT06358573Triple-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer
DrugINT230-6
Swiss Cancer Institute
Phase 2
61
Aarau, Basel, Bellinzona, Chur, Liestal, Sankt Gallen, Winterthur, Zurich
2024-10-24
Recruiting
Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT06401980Metastatic Castration-resistant Prostate Cancer
DrugDarolutamide
Swiss Cancer Institute
Phase 2
162
Aarau, Baden, Bellinzona, Bern, Chur, Geneva, Lausanne, Lucerne
2024-10-22
Recruiting
Bristol-Myers Squibb
Phase 3
1,000
Lausanne, Bellinzona, Basel, Münsterlingen
2024-10-07
Active, closed
Genmab
Phase 3
621
Bellinzona, Geneva, Lausanne, Sankt Gallen
2024-06-25
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
220
Geneva, Bellinzona
2024-06-20
Active, closed
Ivy Brain Tumor Center
Phase 3
450
Basel, Bellinzona, Bern, Zurich
2024-06-19
Recruiting
Ente Ospedaliero Cantonale, Bellinzona
Not applicable
63
Bellinzona
2024-06-12
Active, closed
The Lymphoma Academic Research Organisation
Phase 3
790
Bellinzona, Chur, Geneva, Olten, Thun, Villars-sur-Glâne
2024-06-07
Active, closed
International Extranodal Lymphoma Study Group (IELSG)
Phase 3
122
Bellinzona, Bern
2024-05-21
Recruiting
International Extranodal Lymphoma Study Group (IELSG)
Observational
300
Basel, Bellinzona, Geneva, Sankt Gallen, Zurich
2024-04-11
Recruiting
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
411
Bellinzona, Zurich
2024-03-15
Active, closed
Swiss Cancer Institute
Not applicable
64
Aarau, Basel, Bellinzona, Bern, Chur, Fribourg, Geneva, Lausanne
2024-03-12
Recruiting
Bristol-Myers Squibb
Phase 1/2
460
Bellinzona, Basel, Geneva
2023-12-29
Recruiting
Swiss Cancer Institute
Not applicable
128
Aarau, Bellinzona, Chur, Fribourg, Geneva, Lucerne, Zurich
2023-12-21
Active, closed
Merck Sharp & Dohme LLC
Phase 3
710
Basel, Bellinzona, Chur, Bern
2023-12-06
Recruiting
Oncology Institute of Southern Switzerland
Not applicable
30
Bellinzona
2023-11-27
Recruiting
Institut Curie
Not applicable
600
Aarau, Basel, Bellinzona, Bern, Geneva, Lausanne, Lucerne, Sankt Gallen
2023-11-02
Recruiting
Combination Study of Antibiotics With Enzalutamide (PROMIZE)
NCT06126731Metastatic Castration-Resistant Prostate Cancer (mCRPC)
DrugsCiprofloxacin·Metronidazole·Vancomycin·Amoxicillin
Institute of Cancer Research, United Kingdom
Phase 1/2
39
Bellinzona
2023-11-02
Recruiting
Orion Corporation, Orion Pharma
Phase 1/2
315
Bellinzona
2023-10-26
Active, closed
AstraZeneca
Phase 3
5,511
Baden, Basel, Bellinzona, Chur, Frauenfeld, La Chaux-de-Fonds, Lausanne, Lucerne
2023-10-05
Recruiting
Oncology Institute of Southern Switzerland
Phase 2
40
Bellinzona
2023-09-11
Recruiting
Incyte Corporation
Phase 1
570
Bellinzona, Lausanne, Sankt Gallen
2023-07-24
Active, closed
Merck Sharp & Dohme LLC
Phase 1
95
Geneva, Sankt Gallen, Bellinzona
2023-07-06
Recruiting
University Hospital, Geneva
Observational
400
Bellinzona, Bern, Geneva, Lausanne, Lugano, Sankt Gallen, Zurich
2023-04-01
Active, closed
Insel Gruppe AG, University Hospital Bern
Not applicable
36
Basel, Bellinzona, Bern, Winterthur, Zurich
2023-03-29
Active, closed
ETOP IBCSG Partners Foundation
Phase 2
60
Bellinzona, Bern, Geneva, Sankt Gallen
2023-03-27
Recruiting
The Immune Landscape of Epithelial Ovarian Cancer
NCT05984875Epithelial Ovarian Cancer
Oncology Institute of Southern Switzerland
Observational
74
Bellinzona
2022-12-20
Active, closed
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
NCT05688280Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer, Soft Tissue Sarcoma
DrugIP-001
Immunophotonics, Inc.
Phase 1/2
42
Bellinzona, Bern, Chur, Sankt Gallen
2022-11-29
Active, closed
Genmab
Phase 3
549
Aarau, Sankt Gallen, Bellinzona, Chur
2022-09-20
Recruiting
AstraZeneca
Phase 2
454
Basel, Bellinzona, Sankt Gallen
2022-09-06
Active, closed
Incyte Corporation
Phase 1
291
Bellinzona, Bern, Lausanne
2022-07-05
Active, closed
Swiss Cancer Institute
Phase 2
46
Zurich, Baden, Basel, Bellinzona, Bern, Chur, Geneva, Lucerne
2022-06-24
Recruiting
Nuvalent Inc.
Phase 1/2
840
Bellinzona, Lucerne
2022-06-09
Recruiting
UNICANCER
Phase 3
300
Bellinzona, Chur, Sankt Gallen, Viganello, Zurich
2022-04-19
Recruiting
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
NCT05131022Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL)
DrugBexobrutideg
Nurix Therapeutics, Inc.
Phase 1
572
Basel, Bellinzona, Bern, Geneva, Sankt Gallen, Zurich
2022-04-13
Active, closed
Amgen
Phase 1/2
329
Bellinzona, Bern, Geneva, Sankt Gallen, Zurich
2022-02-01
Recruiting
Merck Sharp & Dohme LLC
Phase 1
830
Sankt Gallen, Bellinzona
2021-12-17
By invitation
Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies
NCT05041309Solid and Hematological Malignancies, Autoimmune Diseases
DrugsKITE-197·SPRX002·KITE-753·Tecartus
Kite, A Gilead Company
Observational
1,500
Bellinzona
2021-12-15
Recruiting
Insel Gruppe AG, University Hospital Bern
Phase 3
70
Lausanne, Bellinzona, Chur, Sion, Basel, Bern, Geneva, Lucerne
2021-11-16
Active, closed
GWT-TUD GmbH
Phase 3
70
Basel, Bellinzona, Bern
2021-10-27
Active, closed
International Extranodal Lymphoma Study Group (IELSG)
Phase 2
26
Bellinzona
2021-10-20
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
DrugsBosutinib·Asciminib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 3
405
Bellinzona
2021-10-06
Active, closed
Loxo Oncology, Inc.
Phase 3
600
Bellinzona, Lucerne
2021-09-20
Active, closed
Swiss Cancer Institute
Phase 2
46
Aarau, Basel, Bellinzona, Bern, Chur, Geneva, Männedorf, Olten
2021-06-25
Active, closed
Swiss Cancer Institute
Phase 2
260
Aarau, Baden, Basel, Bellinzona, Bern, Chur, Fribourg, Geneva
2021-06-25
Active, closed
AstraZeneca
Phase 3
506
Basel, Bellinzona, Lausanne, Lucerne
2021-06-22
Recruiting
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
NCT04774159Peripheral Arterial Disease, Atherosclerosis of Extremities, Inflammation
DrugColchicine
Population Health Research Institute
Phase 3
6,150
Basel, Bellinzona, Fribourg, Geneva, Zurich
2021-05-06
Active, closed
Incyte Corporation
Phase 3
654
Basel, Bellinzona, Bern, Sankt Gallen, Winterthur, Zurich
2021-04-15
Recruiting
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
DrugNemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
490
Bern, Bellinzona
2021-04-05
Active, closed
Loxo Oncology, Inc.
Phase 3
238
Bellinzona
2021-03-09
Active, closed
German CLL Study Group
Phase 3
897
Aarau, Baden, Basel, Bellinzona, Bern, Brig, Chur, Fribourg
2021-03-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
747
Geneva, Zurich, Bellinzona, Chur
2021-02-25
Active, closed
International Extranodal Lymphoma Study Group (IELSG)
Observational
496
Geneva, Bellinzona
2020-12-01
Recruiting
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
NCT04111978Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms, Peritoneal Neoplasms, High-grade Serous Ovarian Carcinoma (HGSOC)
DrugLetrozole
Swiss GO Trial Group
Phase 3
540
Aarau, Basel, Bellinzona, Sion, Baden, Bern, Chur, Frauenfeld
2020-11-05
Recruiting
Tumor Molecular Profiling in Early Phase Clinical Trials
NCT04510766Advanced Solid Tumor, Lymphoma
Oncology Institute of Southern Switzerland
Observational
40
Bellinzona
2020-10-01
Recruiting
Oncology Institute of Southern Switzerland
Observational
60
Bellinzona
2020-09-24
Recruiting
University of Birmingham
Phase 1/2
1,672
Aarau, Basel, Bellinzona, Bern, Geneva, Lausanne, Lucerne, Sankt Gallen
2020-09-17
Active, closed
ADC Therapeutics S.A.
Phase 3
440
Bellinzona
2020-09-16
Active, closed
Swiss Cancer Institute
Phase 2
90
Aarau, Baden, Basel, Bellinzona, Bern, Chur, Geneva, Sankt Gallen
2020-07-15
Recruiting
Safety and Early Signs of Efficacy of IL12-L19L19.
NCT04471987Advanced Solid Tumor, Metastatic Solid Tumor
Philogen S.p.A.
Phase 1
80
Basel, Bern, Geneva, Bellinzona
2020-07-01
Recruiting
Ente Ospedaliero Cantonale, Bellinzona
Observational
289
Bellinzona, Geneva
2020-04-27
Recruiting
Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)
NCT05017142Optic Neuritis, Transverse Myelitis, Acute Disseminated Encephalomyelitis, Multiple Sclerosis
University of Bern
Observational
500
Aarau, Sankt Gallen, Lausanne, Winterthur, Bellinzona, Chur, Basel, Bern
2020-04-14
Recruiting
Amgen
Phase 1
479
Bellinzona, Chur, Lausanne, Sankt Gallen
2020-03-04
Active, closed
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3
777
Aarau, Basel, Bellinzona, Bern, Fribourg, Geneva, Lausanne, Lucerne
2019-12-20
Active, closed
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 2
140
Aarau, Basel, Bellinzona, Bern, Fribourg, Geneva, Lausanne, Lucerne
2019-12-05
Recruiting
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
NCT04221035High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy
DrugsDinutuximab beta·Vindesine·Cyclophosphamid·Thiotepa
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3
800
Aarau, Basel, Bellinzona, Bern, Geneva, Lausanne, Lucerne, Sankt Gallen
2019-11-05
Recruiting
Kantonsspital Winterthur KSW
Observational
600
Winterthur, Bellinzona, Chur, Lucerne, Zurich
2019-10-19
Recruiting
Pierre Fabre Pharma GmbH
Observational
750
Bellinzona, Aarau, Bern, Chur, Lausanne, Lucerne, Winterthur, Zurich
2019-10-17
Active, closed
Niguarda Hospital
Phase 2
28
Bellinzona, Lucerne, Zurich
2019-10-04
Active, closed
MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas
NCT03697512Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma
DrugsIbrutinib·Rituximab
International Extranodal Lymphoma Study Group (IELSG)
Phase 2
175
Bellinzona, Baden, Bern, Geneva, Zurich
2019-09-27
Recruiting
University Hospital Muenster
Phase 3
683
Aarau, Basel, Bellinzona, Bern, Geneva, Lausanne, Lucerne, Sankt Gallen
2019-08-23
Active, closed
Swiss Cancer Institute
Phase 2
135
Basel, Bellinzona, Bern, Chur, Lausanne, Sankt Gallen, Sion, Winterthur
2019-07-29
Recruiting
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3
1,210
Aarau, Baden, Bellinzona, Bruderholz, Chur, Münsterlingen, Sankt Gallen, Zurich
2019-06-06
Active, closed
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3
968
Basel, Bellinzona, Bern, Fribourg, Geneva, Lucerne, Sankt Gallen, Zurich
2019-03-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
714
Zuerich, Bellinzona, Geneva
2018-12-17
Active, closed
Merck Sharp & Dohme LLC
Phase 2
329
Zuerich, Geneva, Bellinzona
2018-12-12
Active, closed
1st Line Durvalumab in PS 2 NSCLC Patients
NCT03620669NSCLC Stage IV, NSCLC Stage IIIB
DrugDurvalumab
Swiss Cancer Institute
Phase 2
48
Aarau, Baden, Basel, Bellinzona, Bern, Chur, Fribourg, Geneva
2018-12-04
Recruiting
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
NCT03567889Melanoma Stage IIIB, Melanoma Stage IIIC, Melanoma Stage IIID
DrugDaromun
Philogen S.p.A.
Phase 3
186
Basel, Bellinzona, Bern, Geneva, Sankt Gallen, Zurich
2018-09-20
Active, closed
Merck Sharp & Dohme LLC
Phase 3
976
Basel, Bern, Geneva, Sankt Gallen, Lausanne, Zurich, Bellinzona, Chur
2018-09-12
Recruiting
Martin Schrappe
Phase 3
5,000
Aarau, Basel, Bellinzona, Bern, Geneva, Lausanne, Lucerne, Sankt Gallen
2018-07-15
Recruiting
Swiss Registry for Neuromuscular Disorders
NCT05102916SMA, DMD, BMD, IMD
University of Bern
Observational
2,000
Aarau, Bellinzona, Lugano, Lausanne, Basel, Bern, Geneva, Lucerne
2018-06-20
Active, closed
Oncology Institute of Southern Switzerland
Observational
370
Bellinzona, Locarno
2018-03-01
Recruiting
Swiss Rare Disease Registry (SRDR)
NCT05179863Rare Diseases
University of Bern
Observational
500,000
Aarau, Basel, Bellinzona, Bern, Geneva, Lausanne, Sankt Gallen, Zurich
2018-01-01
Recruiting
Oncology Institute of Southern Switzerland
Observational
600
Bellinzona
2017-12-15
Recruiting
AbbVie
Observational
500
Aarau, Thun, Lucerne, Neuchâtel, Sankt Gallen, Winterthur, Bellinzona, Münsterlingen
2017-12-04
Active, closed
Institute of Cancer Research, United Kingdom
Phase 2/3
113
Bellinzona, Geneva, Sankt Gallen, Zurich
2017-11-27
Active, closed
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
885
Bellinzona, Bern, Geneva
2017-09-25
Recruiting
Liquid Biopsy in Mature B-cell Tumors
NCT03280394Mature B-Cell Neoplasm
Oncology Institute of Southern Switzerland
Observational
444
Bellinzona
2017-09-01
Active, closed
University Hospital Muenster
Phase 3
650
Aarau, Basel, Bellinzona, Bern, Geneva, Lausanne, Lucerne, Sankt Gallen
2017-08-03
Recruiting
Prostate Cancer Clinical Trials Consortium
Observational
5,000
Bellinzona, Basel, Chur, Sankt Gallen, Zurich
2017-07-21
Recruiting
Swiss Cerebral Palsy Registry
NCT04992871Cerebral Palsy
University of Bern
Observational
15,000
Aarau, Basel, Bellinzona, Bern, Biel, Geneva, Lausanne, Lucerne
2017-06-19
Recruiting
Diagnosis of Tuberculosis in Swiss Children
NCT03044509Tuberculosis, Mycobacterium Tuberculosis
University Children's Hospital Basel
Observational
190
Aarau, Basel, Bellinzona, Bern, Geneva, Lucerne, Sankt Gallen, Zurich
2017-05-12
Recruiting
Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in Switzerland
NCT03124212Hereditary Breast and Ovarian Cancer, Lynch Syndrome
University of Basel
Observational
700
Fribourg, Geneva, Delémont, Winterthur, Basel, Bellinzona, Bern
2017-04-01
Active, closed
University of Birmingham
Phase 3
700
Aarau, Basel, Bellinzona, Bern, Geneva, Lausanne, Lucerne, Sankt Gallen
2016-04
Active, closed
Phase III Radium 223 mCRPC-PEACE III
NCT02194842Prostate Cancer
DrugsRa223·Enzalutamide
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
446
Bellinzona, Sankt Gallen, Zurich
2015-10
Active, closed
Alliance Foundation Trials, LLC.
Phase 3
5,796
Baden, Thun, Geneva, Bellinzona, Locarno, Chur, Basel, Fribourg
2015-08
Active, closed
AstraZeneca
Phase 3
1,118
Bellinzona, Lausanne
2015-07-21
Active, closed
ETOP IBCSG Partners Foundation
Not applicable
518
Bern, Thun, Baden, Basel, Bellinzona, Frauenfeld, Geneva, Lausanne
2014-12-04
By invitation
Juvenile Inflammatory Rheumatism (JIR) Cohorte
NCT02377245Arthritis, Juvenile Rheumatoid
Michaël Hofer
Observational
15,000
Lausanne, Aarau, Basel, Bellinzona, Chur, Lucerne, Lugano, Sankt Gallen
2014-01
Active, closed
International Extranodal Lymphoma Study Group (IELSG)
Phase 2
112
Bellinzona
2013-12
Active, closed
Novartis Pharmaceuticals
Phase 1/2
259
Bellinzona
2013-10-22
Active, closed
International Extranodal Lymphoma Study Group (IELSG)
Not applicable
540
Bellinzona, Bern, Olten, Sankt Gallen
2012-10
Active, closed
AstraZeneca
Phase 1
197
Bellinzona
2008-10-27
Rows per page Showing 1–148 of 148
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Swiss investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 15 November 2026. https://priyalifescience.com/clinical-trials-switzerland/city/bellinzona

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Switzerland and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,249 studies in total at the last sync on 12 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 148 of those studies with a site in Bellinzona.

How many clinical trials are recruiting in Bellinzona?

86 of the 148 studies on this page are recruiting new participants as of the 12 Nov 2026, 03:18 UTC sync. A further 3 have not yet opened recruitment, 57 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Bellinzona), 148 studies
PhaseStudiesRecruitingShare
Phase 3482032.4%
Observational302320.3%
Phase 2291519.6%
Not applicable14109.5%
Phase 1/21187.4%
Phase 11066.8%
Phase 2/3644.1%

Most active sponsors

Lead sponsors with the most studies (Bellinzona)
Lead sponsorStudiesRecruiting
Swiss Cancer Institute158
Merck Sharp & Dohme LLC137
Oncology Institute of Southern Switzerland109
International Extranodal Lymphoma Study Group (IELSG)92
Bristol-Myers Squibb65
AstraZeneca51
European Organisation for Research and Treatment of Cancer - EORTC53
Incyte Corporation53
Stichting Hemato-Oncologie voor Volwassenen Nederland52
Ente Ospedaliero Cantonale, Bellinzona43
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.